Home › Trials › NCT05550298

Understanding respiratory viral infections in pediatric transplant recipients

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

Observational Arkansas Children's Hospital Research Institute · NCT05550298

This study is trying to see if measuring respiratory viruses before a transplant can help predict which kids might get respiratory infections afterward.

Quick facts

Study typeObservational
Enrollment2000 (estimated)
AgesN/A to 18 Years
SexAll
SponsorArkansas Children's Hospital Research Institute Academic / other
Locations27 sites (Birmingham, Alabama and 26 other locations)
Trial IDNCT05550298 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the relationship between pre-transplant respiratory viral load and the occurrence of respiratory viral infections (RVI) in pediatric patients who have undergone hematopoietic cell or solid organ transplants. Participants will provide nasal swabs and blood samples at enrollment and if they develop an RVI within one year post-transplant. The study also seeks to develop predictive classifiers based on immunological profiles collected before and after the transplant to identify those at risk for acute respiratory viral infections. The goal is to improve patient outcomes by enhancing pre-transplant screening processes.

Who should consider this trial

Good fit: Ideal candidates are children under 18 years scheduled to receive a hematopoietic cell transplant or solid organ transplant.

Not a fit: Patients who are not undergoing a transplant or are over 18 years old may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to better predictive tools for preventing respiratory viral infections in vulnerable pediatric transplant recipients.

How similar studies have performed: While this approach is novel in the context of pediatric transplant recipients, similar studies in adult populations have shown promise in predicting viral infections post-transplant.

Eligibility criteria

Show full inclusion / exclusion criteria 
Recipient Inclusion Criteria

* Less than 18 years at the time of anticipated transplant
* Participant meets one of the following criteria:

  1. scheduled to receive allogeneic hematopoietic cell transplant within 14 days of enrollment or
  2. Scheduled to or received solid organ transplant within 7 days before or after enrollment
* Participant is receiving care at the time of enrollment at one of the study participating institutions.
* Parent/guardian willing and able to provide informed consent, and if appropriate, child willing and able to provide informed assent.

Donor Inclusion Criteria

* Donor for HCT recipient enrolled on the VIPER study.
* Willing and able to provide informed consent.

Exclusion Criteria:

Recipient Exclusion Criteria

None

Donor Exclusion Criteria

* Is not an HCT donor for a participant enrolled on the VIPER study.
* Not available to provide pre-transplant research blood sample.

Where this trial is running

Birmingham, Alabama and 26 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Hematopoietic Cell TransplantSolid Organ TransplantRespiratory Viral Infection
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.